Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) - February 23-25, 2023 / San Diego, CA
Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Immune Response Following COVID-19 Vaccination (mRNA or non-mRNA) in Patients with Relapsing Multiple Sclerosis Treated with the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib: An Update
Bar-Or | Poster #108
Emergence of a Unique T Cell Population Associated with Cladribine Tablet Treatment in Multiple Sclerosis
Cantoni | Poster #141
Pregnancy and Infant Outcomes from an Ongoing Worldwide Surveillance Program of Cladribine Tablets: 5-Year Pharmacovigilance Results From MAPLE-MS
Hellwig | Poster #482
The Bruton’s Tyrosine Kinase Inhibitor Evobrutinib Demonstrates Superior Efficacy in Targeting Compartmentalized Neuroinflammation Compared to Anti-CD20 Treatment
Kebir | Poster #149
Neurofilament Light Chain Levels and Disease Activity During Long-term Treatment of Relapsing Multiple Sclerosis with the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib
Kuhle | Poster #030
Stabilization of Cognitive Function in Patients with Highly Active Relapsing Multiple Sclerosis Treated with Cladribine Tablets During the 2-Year CLARIFY-MS Study
Langdon | Poster #090
Characteristics and Treatment Patterns of Patients with Multiple Sclerosis Initiating Cladribine Tablets in the United States
Lee | Poster #374
Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib for Relapsing Multiple Sclerosis over 3.5 Years of Treatment: An Ongoing phase 2 Open-Label Extension
Montalban | Poster #075
A Cross-Sectional Survey Evaluating Cladribine Tablets Treatment Patterns Among Patients with Multiple Sclerosis Across the US Enrolled in the MS LifeLines Patient Support Program
Nicholas | Poster #441
Self-Reported Adherence and Interval Safety from the US Phase IV MASTER-2 and CLICK-MS Studies of Cladribine Tablets in Patients with Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Prior Disease-Modifying Therapy
Robertson |Poster #088
Stability of Employment Status Among Patients with Highly Active Relapsing Multiple Sclerosis During the 2-Year CLARIFY-MS Study
Selmaj | Poster #089
Evobrutinib Therapeutic Response is Associated with an Increase in the Number and Maturation of Peripheral and Central Classical Dendritic Cells
Serrano-Regal | Poster #142
Real-World Treatment Patterns and Effectiveness of Cladribine Tablets in Patients with Relapsing Forms of Multiple Sclerosis in the United States
Song | Poster #397
Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study
Wiendl |Poster #008
This site is intended for US healthcare professionals only.
DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.
US-MULNP-00023 09/24
By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.
We use cookies so that we can offer you the best possible website experience. This includes cookies which are necessary for the operation of the website and to manage our corporate commercial objectives, as well as other cookies which are used solely for anonymous statistical purposes, for more comfortable website settings, or for the display of personalized content. You are free to decide which categories you would like to permit. Please note that depending on the settings you select, the full functionality of the website may no longer be available. You may review and change your choices at any time. Further information can be found in our Privacy Policy.
These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.
In order to continuously improve our website, we anonymously track data for statistical and analytical purposes. With these cookies we can, for example, track the number of visits or the impact of specific pages of our web presence and therefore optimize our content.
These cookies allow us to provide more comfort for you. For example, previously searched products or services can be reloaded again after revisiting our website and you won’t need to enter all the details again. We can also detect if you need assistance with using our website and therefore offer you direct customer support.
These cookies are used to display personalized content matching your interests. We can display personalized and relevant services to ensure you are always up to date on related offers.
Help us direct you to the right information by selecting one of the following options: